^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    nab-paclitaxel/rituximab nanoparticle (AR160)

    i
    Other names: AR160
    Company:
    Mayo Clinic, Sorrento
    Drug class:
    Bcl2 inhibitor, CD20 inhibitor, Tubulin inhibitor
    Related drugs:
    1year
    A First in Human Phase I Trial (LS1681) of Abraxane/Rituximab 160 Nm Nanoparticle (AR160) in Relapsed Refractory B-Cell Lymphomas Including Transformed Follicular Lymphoma: A Final Report (ASH 2023)
    AR160 therapy is a novel drug delivery system incorporating significantly lower doses of paclitaxel and rituximab that is safe and demonstrates promising clinical activity in patients with low-grade and high-grade previously treated B-cell lymphomas. This principle of treatment is applicable to other disorders. Further clinical testing is warranted in these patient populations.
    P1 data
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 expression • MYC rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • albumin-bound paclitaxel • nab-paclitaxel/rituximab nanoparticle (AR160)
    over1year
    Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial (clinicaltrials.gov)
    P1, N=9, Completed, Mayo Clinic | Suspended --> Completed | N=18 --> 9 | Trial completion date: Apr 2024 --> May 2023 | Trial primary completion date: Oct 2023 --> May 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • albumin-bound paclitaxel • nab-paclitaxel/rituximab nanoparticle (AR160)
    over1year
    Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial (clinicaltrials.gov)
    P1, N=18, Suspended, Mayo Clinic | Trial primary completion date: Apr 2023 --> Oct 2023
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • albumin-bound paclitaxel • nab-paclitaxel/rituximab nanoparticle (AR160)
    almost2years
    Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial (clinicaltrials.gov)
    P1, N=18, Suspended, Mayo Clinic | Trial completion date: Jun 2023 --> Apr 2024 | Recruiting --> Suspended
    Trial completion date • Trial suspension
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • albumin-bound paclitaxel • nab-paclitaxel/rituximab nanoparticle (AR160)
    over2years
    Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Mayo Clinic | Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • albumin-bound paclitaxel • nab-paclitaxel/rituximab nanoparticle (AR160)